Related Experiment Video
Updated: Jun 20, 2026

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
Published on: August 8, 2025
Successful treatment of a large hemangioma with propranolol
Waseem Mousa1, Kirsten Kues, Ellen Haas
1Department of Dermatology, Venereology and Allergology, Georg August University Göttingen, Germany.
Insights
Propranolol effectively treats severe infantile hemangiomas, stopping growth and causing regression. This non-selective beta-blocker offers a well-tolerated option for infants when managed by pediatricians and dermatologists.
Area of Science:
- Pediatric Oncology
- Dermatology
- Vascular Biology
Background:
- Infantile hemangiomas are common pediatric vascular tumors, with unknown etiology.
- Severe cases may present with rapid growth and ulceration, necessitating intervention.
- Current management strategies for severe infantile hemangiomas are evolving.
Observation:
- A premature infant with a large thoracic hemangioma experienced rapid growth and ulceration.
- Systemic therapy was initiated due to the severity of the condition.
- Treatment involved oral propranolol, a non-selective beta-blocker.
Findings:
- Propranolol therapy halted hemangioma expansion within days.
- Significant tumor regression was observed after 18 weeks of continuous treatment.
- The treatment was well-tolerated by the infant.
Implications:
- Propranolol shows promise as an effective and tolerable treatment for severe infantile hemangiomas.
- Interdisciplinary cooperation between dermatology and pediatrics is crucial for optimal management.
- Further research into propranolol's role in pediatric vascular tumors is warranted.
Abstract:
Hemangiomas are the most common vascular tumors in children. They occur in 8-12% of all infants and in 22% of premature infants (female: male = 3: 1). Hemangiomas are usually sporadic; their etiology is unknown. A premature female infant, born at 28 weeks of gestation, presented with a large hemangioma of the right thoracic wall. Within the first few weeks, the hemangioma showed rapid horizontal and vertical growth as well as ulceration, which led us to initiate systemic therapy. The effectiveness of propranolol (non-selective ss-blocker) in the management of severe cases of hemangioma has been shown in a recent series of cases. We began oral propranolol treatment, in close interdisciplinary cooperation. After a few days of therapy, the tumor had stopped expanding. After 18 weeks, there has been marked regression but the therapy is still being continued. We propose that propranolol may be an effective and relatively well tolerable alternative in the management of selected cases of severe hemangiomas in infancy, providing interdisciplinary cooperation between dermatologists and pediatricians is available.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Aneurysm III: Interprofessional Care
Antihypertensive Drugs: Vasodilators
